Arterys Earns FDA Clearance for Image Analysis Software

The Terminator is coming. Arterys's novel algorithm based on artificial intelligence and machine learning has just been approved by the Food and Drug Administration. Using a “deep learning algorithm”, the new software will significantly accelerate the MRI analyzation process. 

Arterys is a SaaS-based imaging analytics company that is attempting to revolutionize the way MRI scans are generated. In addition to their Cardio DL software, the company creates technology that provides detailed measurements of the volume of each ventricle, so that physicians can get accurate assessments of the heart.

Their new software automates an otherwise lengthy analyses of cardiac MRI images to show editable contours of the interior and exteriors of the heart’s ventricles in under 10 seconds. Normally, it would take a doctor around 30 minutes to an hour to come up with an analysis.

After scanning and reading 1,000 cases, the new imaging platform has developed an artificial neural network to effectively diagnose heart problems. With its new FDA clearance and CE mark, the software can now be used in clinical settings, where it will inevitably gather more cases.

Founded by Stanford University alumni Fabien Beckers, John Axerio-Cilies, Shreyas Vasanawala, and Albert Hsiao, Arterys received FDA approval in November for a software that quantifies cardiac flow and function measurements. The program is expected to be released through a partnership with GE Healthcare’s ViosWorks product.